Howard S Hochster

Nov 21, 2024 | onclive.com | Howard S Hochster

CommentaryVideoNovember 21, 2024Author(s):Howard S. Hochster, MD, FACP, discusses the role of cooperative group clinical trials in bridging the gap between academic and community cancer centers. Clinical trials are important because they give our patients tomorrow’s treatment today, and so we like to bring the state-of-the-art treatments, and the ones that will be the state-of-the-art-treatments, to all our patients through clinical research.”Howard S.

Mar 8, 2024 | brnw.ch | Francesca Battaglin |Howard S Hochster |Donna Niedzwiecki |Richard Goldberg

Get full access to this articleView all available purchase options and get full access to this article. Data SupplementAuthors retain all rights in any data supplements associated with their articles. The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.

Nov 14, 2023 | onclive.com | Howard S Hochster

Howard S. Hochster, MD, discusses the importance of clinical trial participation for patients with cancer and highlights the use of precision medicine across the treatment armamentarium. Howard S.

Nov 9, 2023 | cancernetwork.com | Howard S Hochster

As the shortages of chemotherapy drugs continue to produce day-to-day treatment dilemmas and lead to enforced workarounds for clinicians—not to mention stir high anxiety in patients—we should reflect on how we got here. We should recall that periods of drug shortages have occurred for more than 20 years. We have survived these intermittent disruptions because they involved 1 or 2 drugs at most and have been of shorter duration.

Sep 14, 2023 | cancernetwork.com | Howard S Hochster

With the Inflation Reduction Act of 2022 signed into law, President Joseph R. Biden and the previous Congress established a new process for limiting federal expenditures on drugs, using the leverage of the largest consumer of health care services in the United States (US)—Medicare. Currently, from Medicare’s 2022 budget of $747 billion, Part D drug expenditure accounts for $216 billion (28%).1 Even a 5% saving on these drugs would amount to $10 billion yearly.